Skip to main content
Premium Trial:

Request an Annual Quote

Lucigen Inks Deal to Take Over Sale of Research Products From Illumina Subsidiary

NEW YORK (GenomeWeb) – Lucigen has signed a licensing agreement to take over the manufacture and sale of a portfolio of transposomics, microarray analysis, and transcriptomics products from Illumina subsidiary Epicentre, GenomeWeb has learned.

The exclusive agreement covers a variety of research products including ones from Epicentre's AmpliScribe, CopyControl, MaxPlax, and TransforMax lines. According to Lucigen, the products complement its suite of synthetic biology, next-generation sequencing, genetic amplification, and protein expression tools.

Lucigen said that it will begin offering the products directly to its customers and through its worldwide distribution network beginning on Jan. 1, 2017.

Additional terms of the deal were not disclosed.

"We are excited to expand and enrich our product offering to serve scientists worldwide with unique tools that will deliver innovative and meaningful breakthroughs in life sciences," Lucigen CEO Ralph Kauten said in a statement.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.